1-20 of 27 results for subject:ME/CFS
Librarians' tools
- Search time
- 0.249 seconds
- Solr query time
- 0.004 seconds
- Search query
- subject:ME/CFS
- We searched for
- subject_t:ME/CFS OR subject_t:"Chronic fatigue syndrome" OR subject_t:"Myalgic encephalomyelitis" OR subject_t:"Myalgic encephalopathy" OR subject_ses:9169
Type
House
Session
Month
Department
Member
More
Primary member
Answering member
Legislative stage
Legislation
Subject
More
Publisher
To ask the Secretary of State for Health how much his Department spends through Birmingham and Solihull Mental Health NHS Foundation Trust on the detection and treatment of Chronic Fatigue Syndrome/ME; and what proportion of such funding is spent in each parliamentary constituency in Birmingham.
To ask the Secretary of State for Health how much his Department spends through Birmingham and Solihull Mental Health NHS Foundation Trust on the detection and treatment of Chronic Fatigue Syndrome/ME; and what proportion of such funding is spent in each parliamentary constituency in Birmingham.
The information requested is not held centrally. Clinical commissioning groups (CCGs) commission services for chronic fatigue syndrome/myalgic encephalopathy.
The information may be available from the National Health Service Birmingham South Central CCG.
To ask Her Majesty’s Government who is the author of the material on chronic fatigue syndrome issued by Capita for training purposes under its responsibilities as a personal independence payment assessor under chapter 4.2 of the PIP Assessment Guide.[HL924]
To ask Her Majesty’s Government who is the author of the material on chronic fatigue syndrome issued by Capita for training purposes under its responsibilities as a personal independence payment assessor under chapter 4.2 of the PIP Assessment Guide.[HL924]
Capita have produced the training material for their health professionals undertaking PIP assessments. It was developed in-house by qualified doctors, in line with current clinical guidelines, and includes some condition-specific information such as the material on chronic fatigue syndrome. This material forms part of an overall training package, approved by DWP, which builds on health professionals’ existing knowledge. This enables them to consider an individual's claim against the PIP assessment criteria and produce a holistic assessment of how their health condition or impairment impacts upon daily living and mobility.
To ask the Secretary of State for Health if he will take steps to encourage research on medically unexplained symptoms as part of wider research on ME and chronic fatigue syndrome.
[161418]
To ask the Secretary of State for Health if he will take steps to encourage research on medically unexplained symptoms as part of wider research on ME and chronic fatigue syndrome.
[161418]
The Department's National Institute for Health Research (NIHR) welcomes funding applications for research into any aspect of human health, including chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME). These applications are subject to peer review and judged in open competition, with awards being made on the basis of the scientific quality of the proposals made.
The Medical Research Council (MRC), which is an independent body funded by the Department for Business, Innovation and Skills, has identified research into CFS/ME as a research priority and the Council has implemented a number of initiatives to stimulate high quality research in this area. The MRC's current priorities for this area are outlined in a highlight notice, which can be found on its website at:
www.mrc.ac.uk/Fundingopportunities/Highlightnotices/CFSME/MRC001747
Applications for research into all aspects of CFS/ME are welcomed by the MRC; this would include research on medically unexplained symptoms.
The MRC is independent in its choice of which research to support and the selection of projects for funding is determined through peer review.
To ask the Secretary of State for Work and Pensions what assessment he has made of the adequacy of training in myalgic encephalomyelitis and chronic fatigue syndrome received by medical practitioners and assessors employed by Atos Healthcare to carry out work capability assessments.
[161158]
To ask the Secretary of State for Work and Pensions what assessment he has made of the adequacy of training in myalgic encephalomyelitis and chronic fatigue syndrome received by medical practitioners and assessors employed by Atos Healthcare to carry out work capability assessments.
[161158]
DWP recognises Chronic Fatigue Syndrome (CFS)/Myalgic Encephalomyelitis (ME) as a real and potentially significantly disabling condition. The assessment of individuals with CFS/ME or any other condition is not dependent on their classification but rather on the disabling effects of the condition.
All health care professionals who undertake assessments on behalf of DWP are required to read an evidence based protocol on CFS/ME as part of their induction training. All health care professionals are required to engage in a programme of continuing medical education which includes modules on CFS.
While the role of the examining health care professional is not to diagnose they are expected to elicit clinical signs relevant to a function assessment. Features such as pain, fatigue and repeatability of symptoms are all considered.
To ask the Secretary of State for Work and Pensions (1) how many individuals with chronic fatigue syndrome have been classified as Fit for Work under the Atos Back to Work assessments;
[160204]
To ask the Secretary of State for Work and Pensions (1) how many individuals with chronic fatigue syndrome have been classified as Fit for Work under the Atos Back to Work assessments;
[160204]
Information on chronic fatigue syndrome is not held, however we do hold information classified in two broader categories by the World Health Organisation International Categorisation of Diseases 2010. Note that the totals are likely to over-estimate the actual numbers with CFS, as these categories include unrelated conditions.
Of those that have had an initial work capability assessment on a new claim for employment and support allowance starting between October 2008 and August 2012, 9,900 had a primary condition in the broader categories which include CFS and were found fit for work. Of those starting their claim between October 2008 and February 2012, 2,100 had their fit for work decision overturned at appeal.
Numbers have been rounded to the nearest 100.
(2) how many individuals with chronic fatigue syndrome have been successful in appealing against a Fit for Work judgement under the Atos Fit for Work assessments.
[160205]
Mr Tom Clarke:
(2) how many individuals with chronic fatigue syndrome have been successful in appealing against a Fit for Work judgement under the Atos Fit for Work assessments.
[160205]
Mr Tom Clarke:
Information on chronic fatigue syndrome is not held, however we do hold information classified in two broader categories by the World Health Organisation International Categorisation of Diseases 2010. Note that the totals are likely to over-estimate the actual numbers with CFS, as these categories include unrelated conditions.
Of those that have had an initial work capability assessment on a new claim for employment and support allowance starting between October 2008 and August 2012, 9,900 had a primary condition in the broader categories which include CFS and were found fit for work. Of those starting their claim between October 2008 and February 2012, 2,100 had their fit for work decision overturned at appeal.
Numbers have been rounded to the nearest 100.
To ask the Secretary of State for Health what recent assessment he has made of the risk of myalgic encephalomyelitis following exposure to the HPV vaccination.
[146291]
To ask the Secretary of State for Health what recent assessment he has made of the risk of myalgic encephalomyelitis following exposure to the HPV vaccination.
[146291]
The Medicines and Healthcare products Regulatory Agency (MHRA) has responsibility for vaccines and medicines safety in the United Kingdom. As with all vaccines and medicines, the MHRA has been closely monitoring the safety of the human papillomavirus (HPV) vaccines.
As well as continuous evaluation of suspected adverse reactions (ADRs) associated with the HPV vaccines reported via the Yellow Card Scheme, the MHRA has also applied statistical techniques using ‘observed versus expected’ analyses of key ADRs of interest to assess safety. The MHRA has recently completed an epidemiological study, using the Clinical Practice Research Datalink, to investigate reports of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) following HPV vaccination. ME/CFS is a naturally-occurring medical condition, and the MHRA's study found no evidence to suggest that the vaccine may be a cause of the condition. The results of this study have been submitted for publication in a peer-reviewed scientific journal.
MHRA's safety analysis of the HPV vaccine has been reviewed by the independent advisory committee, the Commission on Human Medicines (CHM). The CHM has advised that no serious new risks have been identified despite substantial use of the vaccine in the UK and abroad. The benefits of HPV vaccination far outweigh any known side effects.
To ask the Secretary of State for Health what consideration his Department has given to and what discussions officials of his Department have had with the National Institute for Health and Clinical Excellence on issuing separate clinical guidelines for myalgic encephalomyelitis and for other fatiguing disorders set out in the...
To ask the Secretary of State for Health what consideration his Department has given to and what discussions officials of his Department have had with the National Institute for Health and Clinical Excellence on issuing separate clinical guidelines for myalgic encephalomyelitis and for other fatiguing disorders set out in the...
We have had no such discussions.
The National Institute for Health and Clinical Excellence (NICE) published its clinical guideline on the diagnosis and management of chronic fatigue syndrome/myalgic encephalomyelitis (or encephalopathy) in adults and children in August 2007. NICE periodically reviews its published guidance in order to take account of the latest available evidence.
To ask the Secretary of State for Health for what reasons patients with myalgic encephalomyelitis have been prevented from being tissue donors since 2007; and for what reasons recipients of tissue donations from such patients are deemed to be at risk.
[145272]
To ask the Secretary of State for Health for what reasons patients with myalgic encephalomyelitis have been prevented from being tissue donors since 2007; and for what reasons recipients of tissue donations from such patients are deemed to be at risk.
[145272]
I refer my hon. Friend to the written answer I gave him on 27 November 2012, Official Report, column 210W.
To ask the Secretary of State for Health (1) on what (a) advice and (b) evidential basis his Department defines myalgic encephalomyelitis as a psychological condition;
[145273]
To ask the Secretary of State for Health (1) on what (a) advice and (b) evidential basis his Department defines myalgic encephalomyelitis as a psychological condition;
[145273]
The Department considers the condition chronic fatigue syndrome/myalgic encephalomyelitis to be a neurological condition of unknown origin.
We have not carried out any specific assessment of the findings of the PACE trial.
The National Institute for Health and Clinical Excellence (NICE) supports clinical decision-making in the national health service by developing guidance and recommendations on the effectiveness of treatments. NICE routinely reviews the need to update its guidance in order to take account of the latest available evidence. As an independent body, NICE is responsible for assessing which evidence should be considered as part of this process.
(2) what assessment his Department has made of the findings of the PACE trial relating to the effectiveness of (a) cognitive behavioural therapy and (b) graded exercise therapy for people with myalgic encephalomyelitis.
[145274]
Mr Brady:
(2) what assessment his Department has made of the findings of the PACE trial relating to the effectiveness of (a) cognitive behavioural therapy and (b) graded exercise therapy for people with myalgic encephalomyelitis.
[145274]
Mr Brady:
The Department considers the condition chronic fatigue syndrome/myalgic encephalomyelitis to be a neurological condition of unknown origin.
We have not carried out any specific assessment of the findings of the PACE trial.
The National Institute for Health and Clinical Excellence (NICE) supports clinical decision-making in the national health service by developing guidance and recommendations on the effectiveness of treatments. NICE routinely reviews the need to update its guidance in order to take account of the latest available evidence. As an independent body, NICE is responsible for assessing which evidence should be considered as part of this process.
To ask the Secretary of State for Health what discussions officials of his Department have had with the Medical Research Council on the possibility of conducting further research to evaluate the outcomes of studies which have reported evidence of the presence of retroviruses in patients with myalgic encephalomyelitis and chronic...
To ask the Secretary of State for Health what discussions officials of his Department have had with the Medical Research Council on the possibility of conducting further research to evaluate the outcomes of studies which have reported evidence of the presence of retroviruses in patients with myalgic encephalomyelitis and chronic...
Officials have had no discussions.
The Medical Research Council funds (MRC) funds medical research in the field of medical science by awarding grants to research organisations.
Research organisations may submit unsolicited research proposals at any time in any field of research relevant to the MRC's remit. In addition, research organisations can submit proposals in response to calls for proposals and highlight notices, which focus on key strategic areas.
Chronic fatigue syndrome/myalgic encephalomyelitis is currently a highlighted area and a high priority for the MRC and the Council has implemented a number of initiatives to stimulate high quality research in this area. The MRC is independent in its choice of which research to support.
To ask the Secretary of State for Health what assessment he has made of the World Health Organization's classification of chronic fatigue syndrome as a neurological disease; and if he will make a statement.
[142124]
To ask the Secretary of State for Health what assessment he has made of the World Health Organization's classification of chronic fatigue syndrome as a neurological disease; and if he will make a statement.
[142124]
The World Health Organization International Classification of Diseases (ICD-10) classifies chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) under neurological disorders at Reference 93.3 and uses the terms post-viral fatigue syndrome (PVS) and benign myalgic encephalomyelitis. The Department accepts this classification and recognises CFS/ME as a neurological condition of unknown origin.
As the symptoms of CFS/ME resemble those of other forms of debilitating illness, we acknowledge that it is not easy to diagnose single cases of the condition. Clinicians are responsible, within their area of competence, for diagnosing medical conditions and it is not the Department's policy to advise the medical profession on clinical practice.
My Lords, I declare my interests as chairman of Forward-ME, a vice-chair of the All-Party Parliamentary Group on ME and a patron of a number of ME charities. The PACE trial was funded by the MRC, the Department of Health, the Scottish Chief Scientist Office and the Department for Work...
My Lords, I declare my interests as chairman of Forward-ME, a vice-chair of the All-Party Parliamentary Group on ME and a patron of a number of ME charities. The PACE trial was funded by the MRC, the Department of Health, the Scottish Chief Scientist Office and the Department for Work...
We are all very grateful to the noble Countess, Lady Mar, for introducing this debate. I will be very brief and I apologise to her for missing the first minute of her speech. Very surprisingly, we were much earlier than expected and, unfortunately, the name of the previous speaker, the...
We are all very grateful to the noble Countess, Lady Mar, for introducing this debate. I will be very brief and I apologise to her for missing the first minute of her speech. Very surprisingly, we were much earlier than expected and, unfortunately, the name of the previous speaker, the...
Like the noble Lord, Lord Winston, I am grateful to the noble Countess, Lady Mar, for giving us an opportunity to look at this question, although I have some doubts as to whether your Lordships’ House is the best place to evaluate scientific evidence and do the exploration. I think...
Like the noble Lord, Lord Winston, I am grateful to the noble Countess, Lady Mar, for giving us an opportunity to look at this question, although I have some doubts as to whether your Lordships’ House is the best place to evaluate scientific evidence and do the exploration. I think...
My Lords, I thank my noble friend Lady Mar for tabling this Question for Short Debate concerning the PACE trial. I must declare an interest as former chair of East London NHS Foundation Trust. Professor White, a leading researcher in the PACE trial, works as a consultant in that trust...
My Lords, I thank my noble friend Lady Mar for tabling this Question for Short Debate concerning the PACE trial. I must declare an interest as former chair of East London NHS Foundation Trust. Professor White, a leading researcher in the PACE trial, works as a consultant in that trust...
My Lords, I too greatly welcome this debate. This is a terrible condition and we are talking about hundreds of thousands of people who are suffering from it. While it is clear that although there have been many studies relative to the seriousness and pervasiveness of this condition, there is...
My Lords, I too greatly welcome this debate. This is a terrible condition and we are talking about hundreds of thousands of people who are suffering from it. While it is clear that although there have been many studies relative to the seriousness and pervasiveness of this condition, there is...
I will stop at this point.
6.02 pm
I will stop at this point.
6.02 pm